^
    1d
    Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement (clinicaltrials.gov)
    P3, N=100, Active, not recruiting, Rush University Medical Center | Suspended --> Active, not recruiting | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment closed • Trial primary completion date • Head-to-Head
    |
    rifampicin
    6d
    QUANTUM: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (clinicaltrials.gov)
    P3, N=532, Recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rifampicin
    7d
    An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (clinicaltrials.gov)
    P1, N=8, Completed, Precision Biotech Taiwan Corp.
    New P1 trial
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • PB101
    8d
    INSPIRE-BLMZ: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Beijing Chest Hospital
    New P3 trial
    |
    rifampicin
    21d
    Radiation Reprograms Fibroblasts to Drive Prostate Cancer Therapy Resistance. (PubMed, Endocr Relat Cancer)
    Across subcutaneous and orthotopic models, combined treatment with carotuximab and irradiation reproducibly achieved superior tumor volume reduction relative to single-agent therapy. This study identified the BMP/CD105 axis as a key pathway in radiation resistance, highlighting the potential of targeting fibroblastic CD105 with carotuximab to enhance radiation sensitivity.
    Journal
    |
    ENG (Endoglin) • HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2)
    |
    carotuximab IV (ENV-105)
    28d
    FD-TACT: A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (clinicaltrials.gov)
    P3, N=1680, Recruiting, University of Oxford | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Jul 2026
    Enrollment open • Trial completion date • Trial primary completion date • Head-to-Head
    1m
    Chemoresistance mitigation of dual drug-loaded nanoparticles with doxorubicin and curcumin. (PubMed, Cytotechnology)
    This study investigates the characterization and biological effects of Dual Drug-Loaded Nanoparticles on HepG2/doxorubicin (DOX) cells, focusing on the anti-cancer ability of Doxorubicin/Curcumin-Polyethylene Glycol-Polycaprolactone Nanoparticles (DOX/Cur-PEG-PCL-NPs)...These results demonstrate that DOX/Cur-PEG-PCL-NPs effectively reverse chemoresistance and suppress tumor progression through modulation of the Nrf2 pathway and apoptosis induction, offering a promising strategy for targeted liver cancer therapy. The online version contains supplementary material available at 10.1007/s10616-025-00855-y.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • NQO1 (NAD(P)H dehydrogenase, quinone 1)
    |
    curcumin/doxorubicin (iMX-110)
    1m
    Repurposing antibiotics: A dual-action approach against bacteria-induced cancer. (PubMed, Cancer Pathog Ther)
    Antibiotics such as doxycycline, rifampicin, and azithromycin demonstrate anticancer properties by inhibiting angiogenesis, inducing apoptosis, and regulating key pathways including the interleukin (IL)-6 signaling pathway and autophagy-related pathways. By elucidating the pivotal role of biofilms in persistent infections and highlighting untapped therapeutic opportunities in antibiotic repurposing, this review underscores a transformative approach to cancer treatment. This article explores the potential of repurposing antibiotic drugs for cancer treatment and highlights the prospects of drug repurposing strategies.
    Review • Journal
    |
    IL6 (Interleukin 6)
    |
    rifampicin
    2ms
    NT-101 Topical Ophthalmic Solution in Patients With Wet AMD (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, NexThera Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    2ms
    Mechanistic study of ANXA3-mediated endoplasmic reticulum stress promoting M1 macrophage polarization in pulmonary arterial hypertension based on bioinformatics and nine machine learning algorithms. (PubMed, Comput Biol Med)
    This study demonstrates that ANXA3 regulates ERS to drive M1 macrophage polarization and inflammation, which subsequently promotes PASMC function and promotes PAH progression. ANXA3 may serve as a novel immunoinflammatory target and potential therapeutic candidate.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CD68 (CD68 Molecule) • IL18 (Interleukin 18) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF4 (Activating Transcription Factor 4) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • IL1B (Interleukin 1, beta) • ANXA3 (Annexin A3) • TCF4 (Transcription Factor 4)
    |
    semaxanib (SU5416)
    2ms
    ToxZid: Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis (clinicaltrials.gov)
    P=N/A, N=280, Not yet recruiting, Albert Einstein College of Medicine | Trial completion date: Sep 2029 --> Dec 2029 | Trial primary completion date: Mar 2029 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    rifampicin
    2ms
    QUANTUM: A Study of Quabodepistat-containing Regimen for the Treatment of Drug-resistant Pulmonary Tuberculosis (clinicaltrials.gov)
    P3, N=532, Not yet recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P3 trial
    |
    rifampicin